Fortovase FDA Alerts
The FDA Alerts below may be specifically about Fortovase or relate to a group or class of drugs which include Fortovase.
MedWatch Safety Alerts are distributed by the FDA and published by Drugs.com. Following is a list of possible medication recalls, market withdrawals, alerts and warnings.
Recent FDA Alerts for Fortovase
Fortovase (saquinavir soft gelatin capsules)
Roche and FDA notified healthcare professionals about an Important drug interaction warning. Drug-induced hepatitis with marked transaminase elevations has been observed in healthy volunteers receiving rifampin 600 mg once daily in combination with ritonavir 100 mg/saquinavir 1000 mg twice daily (ritonavir boosted saquinavir). Roche now advises prescribers that Rifampin should not be administered to patients also receiving saquinavir/ritonavir (ritonavir boostedsaquinavir) as part of combination antiretroviral therapy (ART) for HIV infection.
[February 2005 - Letter - Roche]